Nektar Therapeutics Amortization of Debt Discount (Premium)
Nektar Therapeutics (NKTR) reported Amortization of Debt Discount (Premium) of -$5.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-14
- Nektar Therapeutics amortization of debt discount (premium) for the quarter ending 2026-06-30 was -$3.57M.
- Nektar Therapeutics amortization of debt discount (premium) for the quarter ending 2026-03-31 was -$1.66M.
- Nektar Therapeutics amortization of debt discount (premium) for the quarter ending 2025-12-31 was -$1.89M.
- Nektar Therapeutics amortization of debt discount (premium) for the quarter ending 2025-09-30 was -$1.43M.
- Nektar Therapeutics amortization of debt discount (premium) for fiscal 2025 was -$5.51M.
- Nektar Therapeutics amortization of debt discount (premium) for fiscal 2024 was -$9.24M.
- Nektar Therapeutics amortization of debt discount (premium) for fiscal 2023 was -$14.86M.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$5.23M 10-Q · filed 2026-08-14 | -$7.12M derived: sum of 3 quarters · filed 2026-08-14 | -$8.55M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$1.66M 10-Q · filed 2026-05-08 | -$3.55M derived: sum of 2 quarters · filed 2026-05-08 | -$4.98M derived: sum of 3 quarters · filed 2026-05-08 | -$5.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$3.32M derived: sum of 2 quarters · filed 2026-03-13 | -$4.19M derived: sum of 3 quarters · filed 2026-08-14 | -$5.51M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$2.30M derived: sum of 2 quarters · filed 2026-08-14 | -$3.63M 10-Q · filed 2025-11-07 | -$5.16M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$869.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$2.19M 10-Q · filed 2026-08-14 | -$3.73M derived: sum of 3 quarters · filed 2026-08-14 | -$5.79M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$1.32M 10-Q · filed 2026-05-08 | -$2.86M derived: sum of 2 quarters · filed 2026-05-08 | -$4.92M derived: sum of 3 quarters · filed 2026-05-08 | -$7.51M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$3.60M derived: sum of 2 quarters · filed 2026-03-13 | -$6.18M derived: sum of 3 quarters · filed 2026-03-13 | -$9.24M 10-K · filed 2026-03-13 |
| 2024-09-30 | -$2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$4.65M derived: sum of 2 quarters · filed 2025-11-07 | -$7.71M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | -$2.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$5.65M 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | -$3.06M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | -$14.86M 10-K · filed 2025-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |